Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (47 quarters reported)
$217M in Q4 2014 → $186M now. Hover for any quarter.
As reported for the quarter ended June 30, 2026. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| Bicara Therapeutics Inc. | 29.1% | Trimmed 24% | 1,822,150 | $54.1M |
| Nuvation Bio Inc. | 24.7% | Unchanged | 8,081,089 | $45.9M |
| KM Kestra Med Technologies Ltd | 14.0% | Unchanged | 1,022,149 | $26M |
| Bridgebio Oncology Therapeutics Inc. | 13.5% | Unchanged | 3,289,661 | $25.1M |
| Beta Bionics Inc. | 11.1% | Unchanged | 1,316,183 | $20.6M |
| Alumis Inc. | 3.7% | Unchanged | 241,255 | $6.79M |
| Sana Biotechnology, Inc. | 1.6% | Unchanged | 843,750 | $2.94M |
| Imagenebio, Inc. | 1.4% | Unchanged | 455,361 | $2.69M |
| EH Engene Holdings Inc. | 0.8% | Unchanged | 876,357 | $1.52M |
| Odyssey Therapeutics Inc. | 0.0% | New | 2,893 | $54.1K |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 8 quarters.
quarter ended June 30, 2026 · filed August 14, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Bicara Therapeutics Inc. | Trimmed | −570,000 | −$16.9M | 29.1% |
| Replimune Group | Exited | −248,672 | −$1.91M | — |
| Odyssey Therapeutics Inc. | New | +2,893 | +$54.1K | — |
quarter ended March 31, 2026 · filed May 15, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Upstream Bio Inc. | Exited | −1,326,293 | −$36M | — |
| Alumis Inc. | Trimmed | −411,968 | −$9.08M | 3.3% |
| KM Kestra Med Technologies Ltd | Trimmed | −351,442 | −$7M | 12.5% |
| Bicara Therapeutics Inc. | Added | +187,500 | +$3.73M | 29.2% |
quarter ended December 31, 2025 · filed February 17, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Beta Bionics Inc. | Trimmed | −603,942 | −$18.4M | 14.0% |
| KM Kestra Med Technologies Ltd | Trimmed | −272,302 | −$7.22M | 12.7% |
| Nuvation Bio | Trimmed | −750,000 | −$6.72M | 25.3% |
| EH Engene Holdings Inc. | Added | +350,000 | +$3.16M | 2.8% |
| Upstream Bio Inc. | Trimmed | −30,000 | −$815K | 12.6% |
| EH Engene Holdings Inc. | Exited | −89,702 | −$63.4K | — |
quarter ended September 30, 2025 · filed November 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Bridgebio Oncology Therapeutics Inc. | New | +3,289,661 | +$38.1M | 17.1% |
| Upstream Bio Inc. | Trimmed | −680,000 | −$12.8M | 11.5% |
| Nuvation Bio | Trimmed | −2,211,639 | −$8.18M | 14.7% |
| Replimune Group | Trimmed | −1,726,531 | −$7.23M | 0.5% |
| Lexeo Therapeutics | Exited | −1,184,636 | −$4.76M | — |
| Imagenebio, Inc. | New | +455,361 | +$3.71M | 1.7% |
| IO Ikena Oncology | Exited | −2,249,123 | −$3.01M | — |
| Beta Bionics Inc. | Trimmed | −68,162 | −$1.35M | 17.2% |
| Immunic Inc. | Exited | −1,788,160 | −$1.25M | — |
| EH Engene Holdings Inc. | Trimmed | −231,800 | −$164K | — |
quarter ended June 30, 2025 · filed August 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Nuvation Bio | Trimmed | −2,029,612 | −$3.96M | 13.9% |
| KM Kestra Med Technologies Ltd. | Trimmed | −150,000 | −$2.49M | 17.7% |
quarter ended March 31, 2025 · filed May 15, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| KM Kestra Med Technologies Ltd. | New | +1,795,893 | +$44.8M | 26.4% |
| Beta Bionics Inc. | New | +1,988,287 | +$24.3M | 14.4% |
| Syros Pharmaceuticals | Exited | −251,270 | −$57.8K | — |
quarter ended December 31, 2024 · filed May 15, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Upstream Bio Inc. | New | +2,036,293 | +$33.5M | 21.7% |
| Lexeo Therapeutics | Trimmed | −1,171,268 | −$7.71M | 5.1% |
| Replimune Group | Trimmed | −486,116 | −$5.89M | 15.5% |
| EH Engene Holdings Inc. | Trimmed | −550,000 | −$3.66M | 2.3% |
quarter ended September 30, 2024 · filed November 14, 2024
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Bicara Therapeutics Inc. | New | +2,204,650 | +$56.2M | 35.1% |
| Morphic Holding | Exited | −159,846 | −$5.45M | — |
| Nuvation Bio | Trimmed | −203,544 | −$466K | 18.7% |
| Alumis Inc | Trimmed | −2 | −$21 | 4.4% |
Loading...
